Recursion (Nasdaq: RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and development, today announced that its Board of Directors has appointed Fred Hassan as Chair, ...
The latest update is out from Recursion Pharmaceuticals ( (RXRX) ).
A Google DeepMind and Stanford study finds simple shapes like a red heart can push AI models such as GPT-5.4 and Claude ...
Recursion Pharmaceuticals reported Q3 2026 GAAP EPS of -$0.22 (missing estimates by $0.01) but revenue of $18.55M (beating estimates by $3.74M), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results